Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction

Clinical and Experimental Allergy

Volumn 44, Issue 6, 2014, Pages 882-894

  Curin, M ^a,b   Weber, M ^b   Thalhamer, T ^c   Swoboda, I ^b   Focke Tejkl, M ^b   Blatt, K ^a   Valent, P ^a   Marth, K ^b   Garmatiuk, T ^b   Gronlund H ^d   Thalhamer, J ^c   Spitzauer, S ^a   Valenta, R ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SALZBURG   (Austria)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Allergen specific immunotherapy; Cat allergy; Fel d 1; Hypoallergenic vaccine; Recombinant allergen; Tolerance induction; Vaccination

Indexed keywords

ANTIALLERGIC AGENT; EPITOPE; FEL D 1 DERIVATIVE; FREUND ADJUVANT; HYBRID PROTEIN; HYPOALLERGENIC VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; UNCLASSIFIED DRUG; ALLERGEN; FEL D 1 PROTEIN, FELIS DOMESTICUS; GLYCOPROTEIN; IMMUNOGLOBULIN G; PEPTIDE; PROTEIN BINDING; RECOMBINANT PROTEIN; VACCINE;

AFFINITY CHROMATOGRAPHY; ALLERGY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BASOPHIL; BLOOD SAMPLING; CAT; CIRCULAR DICHROISM; CODON; CONJUNCTIVITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; ESCHERICHIA COLI; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOTHERAPY; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN INDUCTION; PROTEIN SECONDARY STRUCTURE; RABBIT; RESTRICTION MAPPING; SUBCUTANEOUS IMMUNOTHERAPY; T LYMPHOCYTE; UPREGULATION; VACCINATION; WILD TYPE; ANIMAL; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; RAT;

ALLERGENS; ANIMALS; BASOPHILS; CATS; EPITOPES, T-LYMPHOCYTE; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PEPTIDES; PROTEIN BINDING; RABBITS; RATS; RECOMBINANT PROTEINS; VACCINES;

EID: 84901217801     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12294     Document Type: Article

References (45)

1. Perzanowski MS, Ronmark E, Nold B, Lundback B, Platts-Mills TA. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure. J Allergy Clin Immunol 1999; 103: 1018-24.
2. Burbach GJ, Heinzerling LM, Edenharter G et al. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy 2009; 64:1507-15.
3. Grönlund H, Saarne T, Gafvelin G, van Hage M. The major cat allergen, Fel d 1, in diagnosis and therapy. Int Arch Allergy Immunol 2010; 151:265-74.
4. van Ree R, van Leeuwen WA, Bulder I, Bond J, Aalberse RC. Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy. J Allergy Clin Immunol 1999; 104:1223-30.
5. Kleine-Tebbe J, Kleine-Tebbe A, Jeep S, Schou C, Løwenstein H, Kunkel G. Role of the major allergen (Fel d I) in patients sensitized to cat allergens. Int Arch Allergy Immunol 1993; 100:256-62.
6. Kaiser L, Grönlund H, Sandalova T et al. The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family. J Biol Chem 2003; 278:37730-5.
7. Kristensen AK, Schou C, Roepstorff P. Determination of isoforms, N-linked glycan structure and disulfide bond linkages of the major cat allergen Fel d 1 by a mass spectrometric approach. Biol Chem 1997; 378:899-908.
8. Duffort OA, Carreira J, Nitti G, Polo F, Lombardero M. Studies on the biochemical structure of the major cat allergen Felis domesticus I. Mol Immunol 1991; 28:301-9.
9. Morgenstern JP, Griffith IJ, Brauer AW et al. Amino acid sequence of Fel d I, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci USA 1991; 88:9690-4.
10. Bond JF, Brauer AW, Segal DB, Nault AK, Rogers BL, Kuo MC. Native and recombinant Fel d 1 as probes into the relationship of allergen structure to human IgE immunoreactivity. Mol Immunol 1993; 30:1529-41.
11. Grönlund H, Bergman T, Sandström K et al. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003; 278:40144-51.
12. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
13. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-71.
14. Taylor WW, Ohman JL Jr, Lowell FC. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 1978; 61:283-7.
15. Van Metre TE Jr, Marsh DG, Adkinson NF Jr et al. Immunotherapy decreases skin sensitivity to cat extract. J Allergy Clin Immunol 1989; 83:888-99.
16. Hedlin G, Graff-Lonnevig V, Heilborn H et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991; 87:955-64.
17. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27:860-7.
18. Nanda A, O'Connor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114:1339-44.
19. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30:1423-9.
20. Norman PS, Ohman JL Jr, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-8.
21. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996; 8:1937-45.
22. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53.
23. Worm M, Lee HH, Kleine-Tebbe J et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011; 127:89-97.
24. Saarne T, Kaiser L, Grönlund H, Rasool O, Gafvelin G, van Hage-Hamsten M. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin Exp Allergy 2005; 35:657-63.
25. Saarne T, Neimert-Andersson T, Grönlund H, Jutel M, Gafvelin G, van Hage M. Treatment with a Fel d 1 hypoallergen reduces allergic responses in a mouse model for cat allergy. Allergy 2011; 66:255-63.
26. Niespodziana K, Focke-Tejkl M, Linhart B et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011; 127:1562-70.
27. Schmitz N, Dietmeier K, Bauer M et al. Displaying Fel d 1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009; 206:1941-55.
28. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11:446-9.
29. Grundström J, Neimert-Andersson T, Kemi C et al. Covalent coupling of vitamin D3 to the major cat allergen Fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy. Int Arch Allergy Immunol 2012; 157:136-46.
30. Martínez-Gómez JM, Johansen P, Rose H et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009; 64:172-8.
31. Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001; 15:2042-4.
32. Campana R, Vrtala S, Maderegger B et al. Altered IgE epitope presentation: a model for hypoallergenic activity revealed for Bet v 1 trimer. Mol Immunol 2011; 48:431-41.
33. Whitmore L, Wallace BA. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res 2004; 32(Web Server issue):W668-73.
34. Hauswirth AW, Natter S, Ghannadan M et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002; 110:102-9.
35. Vogel L, Luttkopf D, Hatahet L, Haustein D, Vieths S. Development of a functional in vitro assay as a novel tool for the standardization of allergen extracts in the human system. Allergy 2005; 60:1021-8.
36. Hartl A, Hochreiter R, Stepanoska T, Ferreira F, Thalhamer J. Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a. Allergy 2004; 59:65-73.
37. Mothes-Luksch N, Stumvoll S, Linhart B et al. Disruption of allergenic activity of the major grass pollen allergen Phl p 2 by reassembly as a mosaic protein. J Immunol 2008; 181:4864-73.
38. Westritschnig K, Linhart B, Focke-Tejkl M et al. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J Immunol 2007; 179:7624-34.
39. van Milligen FJ, van 't Hof W, van den Berg M, Aalberse RC. IgE epitopes on the cat (Felis domesticus) major allergen Fel d I: a study with overlapping synthetic peptides. J Allergy Clin Immunol 1994; 93:34-43.
40. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996; 33:399-405.
41. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001; 15:2045-7.
42. Valenta R, Ferreira F, Focke-Tejkl M et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-41.
43. Linhart B, Valenta R. Vaccines for allergy. Curr Opin Immunol 2012; 24:354-60.
44. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11:586-93.
45. Nilsson OB, Adedoyin J, Rhyner C et al. In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One 2011; 6:e24558.